Acquired amegakaryocytic thrombocytopenia: a diagnostic pitfall in refractory thrombocytopenia
Journal of Current Hematology & Oncology Research · 13.11.2026 · 4 (4) · 166-167
DOI: 10.51271/jchor-0102 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Current Hematology & Oncology Research, online erschienen am 13.11.2026. Verfasst von Serkan Güven.
Abstract (Originalsprache)
Acquired amegakaryocytic thrombocytopenia (AAT) is a rare hematologic disorder characterized by severe isolated thrombocytopenia caused by a selective reduction or complete absence of bone marrow megakaryocytes while other hematopoietic lineages remain relatively preserved. Because its initial clinical presentation frequently overlaps with immune thrombocytopenia (ITP), delayed diagnosis and prolonged exposure to ineffective ITP-directed therapies are common in clinical practice.
Zitieren
APA
Güven, S. (2026). Acquired amegakaryocytic thrombocytopenia: a diagnostic pitfall in refractory thrombocytopenia. Journal of Current Hematology & Oncology Research, 4(4), 166-167. https://doi.org/10.51271/jchor-0102
Vancouver
Güven S. Acquired amegakaryocytic thrombocytopenia: a diagnostic pitfall in refractory thrombocytopenia. Journal of Current Hematology & Oncology Research. 2026;4(4):166-167. doi:10.51271/jchor-0102
BibTeX
@article{Gven2026,
author = {Güven, Serkan},
title = {Acquired amegakaryocytic thrombocytopenia: a diagnostic pitfall in refractory thrombocytopenia},
journal = {Journal of Current Hematology & Oncology Research},
year = {2026},
volume = {4},
number = {4},
pages = {166--167},
doi = {10.51271/jchor-0102}
}
EUVIMED